Hepatitis B is a primary source of liver cancer

Share This Post

Hepatitis B is a virus that causes liver infection, and up to 80% of liver cancer patients are attributed to hepatitis B infection. Hepatitis B virus is highly contagious and has multiple modes of transmission, including mother-to-child transmission, infection with blood products, dialysis, partner sex, infusion of drugs, and long-term close contact with infected persons. In most cases, no symptoms will occur after infection, and a hepatitis B infection can be determined by a blood test. An ultrasound test of the liver can assess the extent of liver involvement. The method of prevention is mainly to prevent hepatitis B through vaccination.

There are two stages of hepatitis B, acute and chronic. If a person is exposed to the hepatitis B virus, then the initial infection is called an acute infection. About one-third of infected adults will experience symptoms such as yellow eyes and abdominal pain. Most people are either asymptomatic or have only mild symptoms, which can easily be mistaken for flu or malaria, and children rarely experience symptoms.

When symptoms of acute hepatitis B appear, the patient needs to rest more to replenish water and nutrition. It is recommended to avoid exposure to other factors that may worsen liver inflammation, such as alcohol. There is no specific treatment or cure for acute hepatitis B. After an acute hepatitis B infection, it may fully recover or progress to a chronic disease. Chronic hepatitis B is diagnosed by certain blood markers of hepatitis. Most adults will not develop chronic diseases, but most children who are infected from birth or under five years of age will develop chronic diseases, which may be asymptomatic or occasionally have hepatitis characterized by abdominal pain, yellow eyes, dark urine, or abnormal liver tests . The main problem faced by chronic hepatitis B is the risk of developing cirrhosis and liver cancer.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Seattle Children's Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients
CAR T-Cell therapy

Seattle Children’s Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients

Seattle Children’s Hospital is launching a groundbreaking CAR T-cell clinical trial for pediatric lupus patients. This innovative approach harnesses the body’s immune cells to target and eliminate lupus-affected cells, offering new hope for young patients with this autoimmune disorder. The trial represents a significant advancement in lupus treatment, aiming to improve outcomes and reduce long-term complications for children suffering from this challenging condition.

Efficacy of CAR T Cell Therapy in B-Cell lymphoma Richter Transformation
CAR T-Cell therapy

Efficacy of CAR T Cell Therapy in B-Cell lymphoma Richter Transformation

CAR T cell therapy has shown promising efficacy in treating B-cell lymphoma Richter Transformation, a rare and aggressive disease. This advanced therapy involves genetically modifying a patient’s T cells to target and destroy cancerous B cells. Clinical trials indicate significant response rates, with some patients achieving complete remission. Despite challenges like potential severe side effects, CAR T cell therapy represents a groundbreaking approach, offering hope for improved outcomes in this difficult-to-treat condition.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy